Buying This Beaten-Down ETF Could Double Your Money Over the Next 5 Years

·4-min read
Buying This Beaten-Down ETF Could Double Your Money Over the Next 5 Years

The iShares Biotechnology ETF (NASDAQ: IBB) has delivered a solid double-digit percentage gain. Meanwhile, the SPDR S&P Biotech ETF (NYSEMKT: XBI) is in negative territory year to date and is close to 25% below its February highs. The key to success for the iShares Biotechnology ETF (IBB) has been Moderna (NASDAQ: MRNA).

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting